文献速递遗传性与小管间质肾病

欧洲高草酸尿症联盟:1型原发性高草酸尿症肾衰竭的决定因素

Determinants of Kidney Failure in Primary Hyperoxaluria Type 1: Findings of the European Hyperoxaluria Consortium.
PubMed 文献 · Kidney Int Rep · 2023-08-04

该回顾性研究纳入OxalEurope注册的932例1型原发性高草酸尿症(PH1)患者,分析基因型-表型关联及肾钙质沉着、尿石症和尿草酸/乙醇酸排泄对肾衰竭的影响。结果显示AGXT无效突变纯合子和肾钙质沉着是肾衰竭的最强决定因素。

要点

  • AGXT无效突变纯合子肾衰竭风险最高,中位起病年龄7.8年。
  • c.508G>A和c.454T>A变异患者肾衰竭风险最低,中位起病年龄31.8年。

核心结论

  • AGXT无效变异纯合子和肾钙质沉着是PH1患者肾衰竭的最强决定因素。

研究设计与样本

  • 回顾性研究,纳入OxalEurope注册的932例PH1患者,采用生存分析和混合模型分析。

主要发现

  • 175例维生素B6无反应(无效)纯合子肾衰竭风险最高,中位起病年龄7.8年;155例c.508G>A和c.454T>A变异患者风险最低,中位起病年龄31.8年。
  • 50例c.731T>C纯合子变异患者肾脏生存优于无效纯合子(P=0.003)。
  • 其他潜在维生素B6反应性变异患者预后较差。
  • 后续发生肾衰竭的患者尿草酸排泄较高(P=0.034),而乙醇酸排泄无此差异;但尿草酸个体内变异达41%,导致置信区间宽。

临床怎么用

  • 在PH1管理中,应关注AGXT无效变异纯合子和肾钙质沉着这两个最强肾衰竭决定因素。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Primary hyperoxaluria type 1 (PH1) has a highly heterogeneous disease course. Apart from the c.508G>A (p.Gly170Arg) AGXT variant, which imparts a relatively favorable outcome, little is known about determinants of kidney failure. Identifying these is crucial for disease management, especially in this era of new therapies. METHODS: In this retrospective study of 932 patients with PH1 included in the OxalEurope registry, we analyzed genotype-phenotype correlations as well as the impact of nephrocalcinosis, urolithiasis, and urinary oxalate and glycolate excretion on the development of kidney failure, using survival and mixed model analyses. RESULTS: The risk of developing kidney failure was the highest for 175 vitamin-B6 unresponsive ("null") homozygotes and lowest for 155 patients with c.508G>A and c.454T>A (p.Phe152Ile) variants, with a median age of onset of kidney failure of 7.8 and 31.8 years, respectively. Fifty patients with c.731T>C (p.Ile244Thr) homozygote variants had better kidney survival than null homozygotes (P = 0.003). Poor outcomes were found in patients with other potentially vitamin B6-responsive variants. Nephrocalcinosis increased the risk of kidney failure significantly (hazard ratio [HR] 3.17 [2.03-4.94], P < 0.001). Urinary oxalate and glycolate measurements were available in 620 and 579 twenty-four-hour urine collections from 117 and 87 patients, respectively. Urinary oxalate excretion, unlike glycolate, was higher in patients who subsequently developed kidney failure (P = 0.034). However, the 41% intraindividual variation of urinary oxalate resulted in wide confidence intervals. CONCLUSION: In conclusion, homozygosity for AGXT null variants and nephrocalcinosis were the strongest determinants for kidney failure in PH1.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Metry EL, Garrelfs SF, Deesker LJ, et al. Determinants of Kidney Failure in Primary Hyperoxaluria Type 1: Findings of the European Hyperoxaluria Consortium. Kidney Int Rep. 2023. PMID: 37849991. doi:10.1016/j.ekir.2023.07.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。